They show slight increases in dystrophin, it’s just a case of where you draw the line and define “efficacy”. It’s thought that at least 10% of normal dystrophin levels are required for any noticeable improved physical effect, and the improvements caused by the drug still leave the child with less than 1% of normal levels.
I go back to a point I made over a year ago, in light of DMD parents signing a petition that influenced the FDA’s decision - what Sarepta are selling to parents of newly diagnosed DMD patients is “hope” at little expense to those who get full health coverage, and at a stage when the prognosis is horrible to contemplate, but not yet played out.
Parents would do anything to keep hope of a cure or just an improvement alive.
The EMA rejected the application.
- Forums
- ASX - By Stock
- For General Information
They show slight increases in dystrophin, it’s just a case of...
-
-
- There are more pages in this discussion • 247 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.5¢ |
Change
0.001(1.35%) |
Mkt cap ! $67.61M |
Open | High | Low | Value | Volume |
7.7¢ | 7.8¢ | 7.4¢ | $24.63K | 325.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 142779 | 7.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.5¢ | 8181 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 142779 | 0.073 |
2 | 147362 | 0.072 |
2 | 310000 | 0.071 |
4 | 34299 | 0.070 |
2 | 28980 | 0.069 |
Price($) | Vol. | No. |
---|---|---|
0.075 | 8181 | 1 |
0.078 | 125476 | 3 |
0.079 | 175123 | 2 |
0.080 | 287231 | 3 |
0.081 | 125000 | 2 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |